Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.395 USD | +7.64% | +8.98% | +1.09% |
Sales 2024 * | 23.95M 2B | Sales 2025 * | 72.18M 6.02B | Capitalization | 291M 24.31B |
---|---|---|---|---|---|
Net income 2024 * | -76M -6.34B | Net income 2025 * | -39M -3.25B | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.04 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-8.7
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 43.46% |
Latest transcript on Verrica Pharmaceuticals Inc.
1 day | +8.81% | ||
1 week | +8.98% | ||
Current month | +25.00% | ||
1 month | +25.00% | ||
3 months | +23.54% | ||
6 months | +110.83% | ||
Current year | +1.09% |
Managers | Title | Age | Since |
---|---|---|---|
Ted White
CEO | Chief Executive Officer | 59 | 01/17/01 |
Terence Kohler
DFI | Director of Finance/CFO | 46 | 16/21/16 |
Compliance Officer | 60 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Prygocki
BRD | Director/Board Member | 58 | 01/18/01 |
Paul Manning
CHM | Chairman | 68 | 01/15/01 |
Craig Ballaron
BRD | Director/Board Member | 63 | 13/19/13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.79% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 7.383 | +7.46% | 102 518 |
26/24/26 | 6.87 | +3.31% | 111,046 |
25/24/25 | 6.65 | -2.06% | 297,436 |
24/24/24 | 6.79 | -0.88% | 114,880 |
23/24/23 | 6.85 | +0.88% | 86,267 |
Delayed Quote Nasdaq, April 29, 2024 at 07:51 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.09% | 291M | |
+26.95% | 661B | |
+27.32% | 566B | |
-6.41% | 352B | |
+20.39% | 332B | |
+2.78% | 283B | |
+13.96% | 231B | |
+5.16% | 200B | |
-9.12% | 195B | |
-5.00% | 145B |
- Stock Market
- Equities
- VRCA Stock